Rakuten Securities Inc. Raises Stake in Pfizer Inc. $PFE

Rakuten Securities Inc. raised its position in Pfizer Inc. (NYSE:PFE) by 77.9% during the third quarter, HoldingsChannel reports. The firm owned 48,104 shares of the biopharmaceutical company’s stock after buying an additional 21,058 shares during the quarter. Rakuten Securities Inc.’s holdings in Pfizer were worth $1,225,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PFE. Curio Wealth LLC raised its stake in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer in the 2nd quarter valued at $30,000. True Wealth Design LLC raised its stake in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares in the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at about $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the topic of several research analyst reports. UBS Group initiated coverage on Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target on the stock. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Citigroup initiated coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Finally, Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $27.88.

Pfizer Stock Up 1.6%

PFE stock opened at $25.56 on Thursday. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average price is $25.31 and its 200 day moving average price is $24.98. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a market cap of $145.32 billion, a P/E ratio of 14.86 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is currently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.